Dalbavancin

Revision as of 20:09, 7 April 2021 by Elcatracho (talk | contribs) (See Also)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Antibiotic
  • Dosage Forms: 500 mg/vial; reconstituted concentration 20 mg/ml
  • Routes of Administration: Intravenous
  • Common Trade Names: Dalvance

Adult Dosing

  • 1500 mg as single dose or 1000 mg then 500 mg one week later; infuse over 30 minutes

Pediatric Dosing

  • Safety and efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

  • Maternal risk cannot be ruled out

Lactation risk

  • Fetal risk cannot be ruled out

Renal Dosing

  • CrCl less than 30 mL/min and not receiving hemodialysis: Single-dose regimen, 1125 mg IV infusion; 2-dose regimen, 750 mg IV infusion followed by 375 mg IV infusion 1 week later[1]
  • No adjustment necessary if on hemodialysis

Hepatic Dosing

  • Hepatic impairment, mild (Child-Pugh class A): No adjustment necessary
  • Hepatic impairment, moderate to severe (Child-Pugh class B or C): Appropriate dosage has not been determined

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Gastrointestinal: Clostridium difficile colitis (<2%), Clostridium difficile diarrhea, GI bleed (<2% )
  • Hepatic: ALT/SGPT level raised (0.8%)
  • Immunologic: Hypersensitivity reaction

Common

  • Gastrointestinal: Diarrhea (Up to 4.4%), Nausea (Up to 5.5%)
  • Neurologic: Headache (Up to 4.7%)

Pharmacology

  • Half-life: 8.5 days
  • Metabolism:
  • Excretion: Fecal (20%), Renal (33%)

Mechanism of Action

  • Semisynthetic lipoglycopeptide antibacterial agent that inhibits cell wall peptidoglycan cross-linking
  • Same MOA and class as vancomycin

Comments

See Also

References

  1. Product Information: DALVANCE(R) intravenous injection, dalbavancin intravenous injection. Durata Therapeutics Inc. (per manufacturer), Parsippany, NJ, 2016.